Research programme: alpha-2B adrenoceptor antagonists - Juvantia Pharma

Drug Profile

Research programme: alpha-2B adrenoceptor antagonists - Juvantia Pharma

Alternative Names: Alpha-2B adrenoceptor antagonists research programme - Juvantia Pharma

Latest Information Update: 18 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juvantia Pharma
  • Class
  • Mechanism of Action Alpha 2b adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vascular disorders

Most Recent Events

  • 20 Jul 2005 This programme is still in active development - (BIO-2005)
  • 31 Jan 2001 New profile
  • 31 Jan 2001 Preclinical development for Vascular disorders in Finland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top